Abstract 1898: LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker for the treatment of B7-H4 expressing cancers
Abstract The B7 family protein B7-H4 is highly expressed on a range of solid tumors including breast, ovarian, and endometrial cancers, where it may play a role in immune evasion. In non-cancerous tissues, B7-H4 expression is limited, suggesting it may be a potential target for an antibody drug conj...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 84; no. 6_Supplement; p. 1898 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
22.03.2024
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
The B7 family protein B7-H4 is highly expressed on a range of solid tumors including breast, ovarian, and endometrial cancers, where it may play a role in immune evasion. In non-cancerous tissues, B7-H4 expression is limited, suggesting it may be a potential target for an antibody drug conjugate (ADC). LNCB74 is a human IgG1 antibody conjugated to the potent microtubule disrupting payload monomethyl auristatin E (MMAE) with a drug-to-antibody ratio of 4 (DAR4). The ADC employs a highly selective B7-H4 antibody based upon NextCure’s expertise in B7-H4 tumor biology coupled with a glucuronidase-cleavable, site-specific linkage to an engineered cysteine in the antibody light chain via LegoChem Biosciences’ ConjuAllTM technology. This improves the safety profile and therapeutic index of the agent by a) increasing stability in circulation, b) selectively releasing payload in tumor cells, and c) reducing payload release in off-target cells. LNCB74 was further engineered with a “LALA”-mutant Fc region to minimize uptake and toxicity to immune cells. In a nonhuman primate (NHP) toxicity study, LNCB74 was well tolerated for repeat dosing and provides evidence for a superior safety profile without noticeable side effects. LNCB74 is rapidly internalized by B7-H4-expressing tumor cells, and demonstrates potent, target-specific cytotoxicity on multiple cancer cell lines. In vivo studies demonstrate a strong bystander effect following a single dose administration of LNCB74. A rapid and durable anti-tumor response has been demonstrated in multiple cell-line derived (CDX) and patient-derived xenograft (PDX) tumor models. In summary, LNCB74 is a promising ADC enabling specific targeting of B7-H4 positive cancers across a spectrum of indications.
Citation Format: Daniel P. Fitzgerald, Duc N. Doan, Riley B. Peacock, Shannon M. Kahan, Suvendu Lomash, Stephen Slocum, Kwang Hwa Jung, Hwanhee Oh, Ingrid Meza, Yanira Manzanarez, Shanmugam Selvam, Dallas B. Flies, Chul-Woong Chung, Sol Langermann. LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker for the treatment of B7-H4 expressing cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1898. |
---|---|
AbstractList | Abstract
The B7 family protein B7-H4 is highly expressed on a range of solid tumors including breast, ovarian, and endometrial cancers, where it may play a role in immune evasion. In non-cancerous tissues, B7-H4 expression is limited, suggesting it may be a potential target for an antibody drug conjugate (ADC). LNCB74 is a human IgG1 antibody conjugated to the potent microtubule disrupting payload monomethyl auristatin E (MMAE) with a drug-to-antibody ratio of 4 (DAR4). The ADC employs a highly selective B7-H4 antibody based upon NextCure’s expertise in B7-H4 tumor biology coupled with a glucuronidase-cleavable, site-specific linkage to an engineered cysteine in the antibody light chain via LegoChem Biosciences’ ConjuAllTM technology. This improves the safety profile and therapeutic index of the agent by a) increasing stability in circulation, b) selectively releasing payload in tumor cells, and c) reducing payload release in off-target cells. LNCB74 was further engineered with a “LALA”-mutant Fc region to minimize uptake and toxicity to immune cells. In a nonhuman primate (NHP) toxicity study, LNCB74 was well tolerated for repeat dosing and provides evidence for a superior safety profile without noticeable side effects. LNCB74 is rapidly internalized by B7-H4-expressing tumor cells, and demonstrates potent, target-specific cytotoxicity on multiple cancer cell lines. In vivo studies demonstrate a strong bystander effect following a single dose administration of LNCB74. A rapid and durable anti-tumor response has been demonstrated in multiple cell-line derived (CDX) and patient-derived xenograft (PDX) tumor models. In summary, LNCB74 is a promising ADC enabling specific targeting of B7-H4 positive cancers across a spectrum of indications.
Citation Format: Daniel P. Fitzgerald, Duc N. Doan, Riley B. Peacock, Shannon M. Kahan, Suvendu Lomash, Stephen Slocum, Kwang Hwa Jung, Hwanhee Oh, Ingrid Meza, Yanira Manzanarez, Shanmugam Selvam, Dallas B. Flies, Chul-Woong Chung, Sol Langermann. LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker for the treatment of B7-H4 expressing cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1898. |
Author | Peacock, Riley B. Flies, Dallas B. Chung, Chul-Woong Kahan, Shannon M. Fitzgerald, Daniel P. Slocum, Stephen Manzanarez, Yanira Doan, Duc N. Selvam, Shanmugam Lomash, Suvendu Oh, Hwanhee Langermann, Sol Jung, Kwang Hwa Meza, Ingrid |
Author_xml | – sequence: 1 givenname: Daniel P. surname: Fitzgerald fullname: Fitzgerald, Daniel P. – sequence: 2 givenname: Duc N. surname: Doan fullname: Doan, Duc N. – sequence: 3 givenname: Riley B. surname: Peacock fullname: Peacock, Riley B. – sequence: 4 givenname: Shannon M. surname: Kahan fullname: Kahan, Shannon M. – sequence: 5 givenname: Suvendu surname: Lomash fullname: Lomash, Suvendu – sequence: 6 givenname: Stephen surname: Slocum fullname: Slocum, Stephen – sequence: 7 givenname: Kwang Hwa surname: Jung fullname: Jung, Kwang Hwa – sequence: 8 givenname: Hwanhee surname: Oh fullname: Oh, Hwanhee – sequence: 9 givenname: Ingrid surname: Meza fullname: Meza, Ingrid – sequence: 10 givenname: Yanira surname: Manzanarez fullname: Manzanarez, Yanira – sequence: 11 givenname: Shanmugam surname: Selvam fullname: Selvam, Shanmugam – sequence: 12 givenname: Dallas B. surname: Flies fullname: Flies, Dallas B. – sequence: 13 givenname: Chul-Woong surname: Chung fullname: Chung, Chul-Woong – sequence: 14 givenname: Sol surname: Langermann fullname: Langermann, Sol |
BookMark | eNqdkEFOwzAQRS1UJFrgCEhzARe7jZXArq1AXQAr9pbrTIJLakf2FLWch4MSqwixZjWj__Vm9P-EjXzwyNiNFFMpVXUr1bziZVGo6eJ5JmYFl9VddcbGv_roz37BJilthRBKCjVmX4tNomgsQYbu4elltSwLcAkM9IHQExhfQzINgscD8RY9RkMu-MEgtwn1kddx33Ib_HbfGkLYk-vcp_PtcMMabzFCwg4tuQ-Ezvn3QWhCBHpDoIiGdvlNaGBZ8nUBeOgjppT5E52u2HljuoTXP_OSqceH19Wa2xhSitjoPrqdiUcthc6V6BxX57j6VInO6eb_5b4BfwBuEw |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1158/1538-7445.AM2024-1898 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | 1898 |
ExternalDocumentID | 10_1158_1538_7445_AM2024_1898 |
GroupedDBID | --- -ET 18M 29B 34G 39C 476 53G 5GY 5RE 6J9 AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ADBBV ADNWM AENEX AETEA AFHIN AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 IH2 KQ8 L7B LSO OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 W2D WH7 WOQ YKV YZZ |
ID | FETCH-crossref_primary_10_1158_1538_7445_AM2024_18983 |
ISSN | 1538-7445 |
IngestDate | Fri Aug 23 03:53:37 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6_Supplement |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-crossref_primary_10_1158_1538_7445_AM2024_18983 |
ParticipantIDs | crossref_primary_10_1158_1538_7445_AM2024_1898 |
PublicationCentury | 2000 |
PublicationDate | 2024-03-22 |
PublicationDateYYYYMMDD | 2024-03-22 |
PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-22 day: 22 |
PublicationDecade | 2020 |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationYear | 2024 |
SSID | ssj0005105 |
Score | 4.591979 |
Snippet | Abstract
The B7 family protein B7-H4 is highly expressed on a range of solid tumors including breast, ovarian, and endometrial cancers, where it may play a... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 1898 |
Title | Abstract 1898: LNCB74 is a potent and safe next-generation antibody-drug-conjugate utilizing a cancer selective linker for the treatment of B7-H4 expressing cancers |
Volume | 84 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9pAEF0RGlW5VG3SKknTag69WXZq48V2b0AaoaagJEqk3CyvPwgRgijYh_B78kM7s2uvLUqr0gMGFu3YeJ5mZ8dvZhj7giuUnUQZN4Wddk036AgzEn7HTGwuvvIkEFmXcodH4-7w1v1xx-9aO7sN1lKRCytebcwr-R-t4hjqlbJkt9CsFooD-Bn1i0fUMB7_Scc9QYGKODdsP_Bpb_9zPOh7LjUpj4zHRV7xx5dRlhpz2uNOZJVp1R18nk_FInk2k6diYuK2-KGgkJqB1zubrmTuIlHCYir3LJvlEMeInvfiQMVNrGnq6HP2PXPoUssASa2lXF45e9n0fwdKYFli6F4-Q1ZkEGmsZjOrEZo4n-ariYyZ1cnwxqWlfe-FCt6eFbExtjbY-Gtp8fr6p4vovgz34vscb8HIagY9HJdYX46zZqc9V1WitNINY6VxV_3nShB3Q9kqteYUKaNNOmo4ANXX3xcXTgkT-jRWbyQvrZ7eLOa9tshq6qPcdHE_JDEhiQmVmJDE7LBXjhdwCiJcXNVV77mi4uozl5loKOZ049U0fKyGs3Tzlr0pdznQU5B9x1rpfJ-9HpU8jgP2UiEXSNA3ULiF6RIiULgFxC0QbmENt_AH3ILGLcpQyAONW1C4BcQtIG5B4xYWGUjcQo3bcvbyPePn328GQ7P6l-GjKs0S_vXudj6wNoIrPWTgxF5ip2ioXC_GVyb8xLM7InBTXND8jB8xazvZx9tO-Mj2amCfsHb-VKSf0L_NxWep_F9klKJZ |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+1898%3A+LNCB74+is+a+potent+and+safe+next-generation+antibody-drug-conjugate+utilizing+a+cancer+selective+linker+for+the+treatment+of+B7-H4+expressing+cancers&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Fitzgerald%2C+Daniel+P.&rft.au=Doan%2C+Duc+N.&rft.au=Peacock%2C+Riley+B.&rft.au=Kahan%2C+Shannon+M.&rft.date=2024-03-22&rft.issn=1538-7445&rft.eissn=1538-7445&rft.volume=84&rft.issue=6_Supplement&rft.spage=1898&rft.epage=1898&rft_id=info:doi/10.1158%2F1538-7445.AM2024-1898&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1538_7445_AM2024_1898 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7445&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7445&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7445&client=summon |